Cargando…
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751403/ https://www.ncbi.nlm.nih.gov/pubmed/36530878 http://dx.doi.org/10.3389/fmed.2022.989405 |
_version_ | 1784850464548847616 |
---|---|
author | Cortinovis, Diego Luigi Colonese, Francesca Abbate, Maria Ida Sala, Luca Meazza Prina, Marco Cordani, Nicoletta Sala, Elisa Canova, Stefania |
author_facet | Cortinovis, Diego Luigi Colonese, Francesca Abbate, Maria Ida Sala, Luca Meazza Prina, Marco Cordani, Nicoletta Sala, Elisa Canova, Stefania |
author_sort | Cortinovis, Diego Luigi |
collection | PubMed |
description | Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces the efficacy of applying the treatment to the entire population of patients with SCLC. The lack of treatments able to bind to a specific target has always been a substantial difference to the non-small cell lung cancer (NSCLC) counterpart. Delta-like canonical Notch ligand 3 is a protein frequently overexpressed in SCLC and is therefore being explored as a potentially promising therapeutic target in high-grade neuroendocrine lung cancer. In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failures through new compounds and their possible applications in clinical practice, with a focus on new molecular classification of SCLC. |
format | Online Article Text |
id | pubmed-9751403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97514032022-12-16 Harnessing DLL3 inhibition: From old promises to new therapeutic horizons Cortinovis, Diego Luigi Colonese, Francesca Abbate, Maria Ida Sala, Luca Meazza Prina, Marco Cordani, Nicoletta Sala, Elisa Canova, Stefania Front Med (Lausanne) Medicine Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces the efficacy of applying the treatment to the entire population of patients with SCLC. The lack of treatments able to bind to a specific target has always been a substantial difference to the non-small cell lung cancer (NSCLC) counterpart. Delta-like canonical Notch ligand 3 is a protein frequently overexpressed in SCLC and is therefore being explored as a potentially promising therapeutic target in high-grade neuroendocrine lung cancer. In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failures through new compounds and their possible applications in clinical practice, with a focus on new molecular classification of SCLC. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9751403/ /pubmed/36530878 http://dx.doi.org/10.3389/fmed.2022.989405 Text en Copyright © 2022 Cortinovis, Colonese, Abbate, Sala, Meazza Prina, Cordani, Sala and Canova. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Cortinovis, Diego Luigi Colonese, Francesca Abbate, Maria Ida Sala, Luca Meazza Prina, Marco Cordani, Nicoletta Sala, Elisa Canova, Stefania Harnessing DLL3 inhibition: From old promises to new therapeutic horizons |
title | Harnessing DLL3 inhibition: From old promises to new therapeutic horizons |
title_full | Harnessing DLL3 inhibition: From old promises to new therapeutic horizons |
title_fullStr | Harnessing DLL3 inhibition: From old promises to new therapeutic horizons |
title_full_unstemmed | Harnessing DLL3 inhibition: From old promises to new therapeutic horizons |
title_short | Harnessing DLL3 inhibition: From old promises to new therapeutic horizons |
title_sort | harnessing dll3 inhibition: from old promises to new therapeutic horizons |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751403/ https://www.ncbi.nlm.nih.gov/pubmed/36530878 http://dx.doi.org/10.3389/fmed.2022.989405 |
work_keys_str_mv | AT cortinovisdiegoluigi harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT colonesefrancesca harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT abbatemariaida harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT salaluca harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT meazzaprinamarco harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT cordaninicoletta harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT salaelisa harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons AT canovastefania harnessingdll3inhibitionfromoldpromisestonewtherapeutichorizons |